Alto Neuroscience (ANRO) Capital Expenditures (2023 - 2026)

Alto Neuroscience has reported Capital Expenditures for 4 years, with the latest figure at $941000.0 in Q1 2026.

• Quarterly Capital Expenditures rose 3820.83% year-over-year to $941000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $941000.0 (up 570.5% YoY) and the FY2025 annual result came in at $24000.0, changed N/A from the prior year.
• Capital Expenditures advanced to $941000.0 in Q1 2026 per ANRO's latest filing, from $24000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $941000.0 in Q1 2026 and troughed at -$532000.0 in Q3 2024.
• A 4-year average of $159444.4 and a median of $75000.0 in 2023 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2024 and 2026: Capital Expenditures sank 609.33% in 2024, then surged 3820.83% in 2026.
• Over 4 years, Capital Expenditures stood at $470000.0 in 2023, then plunged by 106.81% to -$32000.0 in 2024, then soared by 175.0% to $24000.0 in 2025, then soared by 3820.83% to $941000.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $941000.0, $24000.0, and -$32000.0 for Q1 2026, Q1 2025, and Q4 2024 respectively.